Published: March 09, 2011
Advanced Cell Technology Comments on Recent Trading
MARLBOROUGH, Mass. - (BUSINESS WIRE) - Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC), a
leader in the field of regenerative medicine, commented today on recent
trading activity in its stock. The Company knows of no business,
clinical or financial reason for the stock's recent significant decline.
The two Phase I/II clinical trials that ACT received FDA clearance on
for its RPE program, including a Phase 1/2 trial in patients with dry
age-related macular degeneration, are proceeding as scheduled.
ACT plans to update investors on its clinical trial progress when it
holds a conference call for the investment community later this month in
conjunction with the filing of its Form 10-K with the Securities and
Exchange Commission.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying
cellular technology in the field of regenerative medicine. For more
information, visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Any statements that are not statements of historical
fact (including statements containing the words "will," "believes,"
"plans," "anticipates," "expects," "estimates," and similar expressions)
should also be considered to be forward-looking statements. There are a
number of important factors that could cause actual results or events to
differ materially from those indicated by such forward-looking
statements, including: limited operating history, need for future
capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and
economic conditions generally. Additional information on potential
factors that could affect our results and other risks and uncertainties
are detailed from time to time in the company's periodic reports,
including the report on Form 10-K for the year ended December 31, 2009.
Forward-looking statements are based on the beliefs, opinions, and
expectations of the company's management at the time they are made, and
the company does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company's management at the
time they are made, and the company does not assume any obligation to
update its forward-looking statements if those beliefs, opinions,
expectations, or other circumstances should change. There can be no
assurance that the Company's clinical trials will be successful.
Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT
Corporate Communications
Bill Douglass, 646-450-3615
or
Russo
Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News
Search News
